| human | Q5 |
| P6178 | Dimensions author ID | 013113543217.79 |
| P1960 | Google Scholar author ID | 67UrhCQAAAAJ |
| P496 | ORCID iD | 0000-0001-8501-7896 |
| P3829 | Publons author ID | 2558023 |
| P1053 | ResearcherID | C-2448-2014 |
| P1153 | Scopus author ID | 7006610653 |
| P10861 | Springer Nature person ID | 013113543217.79 |
| P734 | family name | Götz | Q21506953 |
| Götz | Q21506953 | ||
| Götz | Q21506953 | ||
| P735 | given name | Jürgen | Q2670311 |
| Jürgen | Q2670311 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q36817223 | A decade of tau transgenic animal models and beyond |
| Q36758530 | A local insult of okadaic acid in wild-type mice induces tau phosphorylation and protein aggregation in anatomically distinct brain regions |
| Q53197946 | A neuroprotective role for the DNA damage checkpoint in tauopathy. |
| Q34100797 | Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction |
| Q40116267 | Abeta treatment and P301L tau expression in an Alzheimer's disease tissue culture model act synergistically to promote aberrant cell cycle re-entry |
| Q37678181 | Accelerated aging exacerbates a pre-existing pathology in a tau transgenic mouse model |
| Q47844346 | Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice |
| Q35791948 | Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice |
| Q43475117 | Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice |
| Q48694512 | Active immunization trial in Abeta42-injected P301L tau transgenic mice |
| Q37313547 | Aging in the nervous system of Caenorhabditis elegans. |
| Q38409405 | Aging-Related Dysfunction of Striatal Cholinergic Interneurons Produces Conflict in Action Selection. |
| Q40219547 | Altered levels of PP2A regulatory B/PR55 isoforms indicate role in neuronal differentiation |
| Q48492272 | Altered phosphorylation but no neurodegeneration in a mouse model of tau hyperphosphorylation |
| Q48597411 | Altered phosphorylation of cytoskeletal proteins in mutant protein phosphatase 2A transgenic mice |
| Q34038251 | Altered proteostasis in aging and heat shock response in C. elegans revealed by analysis of the global and de novo synthesized proteome |
| Q112293556 | Altered ribosomal function and protein synthesis caused by tau |
| Q53246225 | Alzheimer's and Parkinson's disease--overlapping or synergistic pathologies? |
| Q36193841 | Alzheimer's disease models and functional genomics-How many needles are there in the haystack? |
| Q37543949 | Alzheimer's disease selective vulnerability and modeling in transgenic mice |
| Q26865759 | Alzheimer's disease, oestrogen and mitochondria: an ambiguous relationship |
| Q37414108 | Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice |
| Q35909424 | Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models |
| Q37824813 | Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease |
| Q42472271 | Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy |
| Q28749702 | Animal models for Alzheimer's disease and frontotemporal dementia: a perspective |
| Q37196122 | Animal models of Alzheimer's disease and frontotemporal dementia |
| Q37596653 | Animal models reveal role for tau phosphorylation in human disease |
| Q36484083 | Antiviral CD8 T cells recognize borna disease virus antigen transgenically expressed in either neurons or astrocytes |
| Q58616121 | Are you me? Amyloid-β blocks the conversation between lysosomes and mitochondria |
| Q73774228 | Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein |
| Q40207204 | Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes |
| Q48578686 | Bio-orthogonal labeling as a tool to visualize and identify newly synthesized proteins in Caenorhabditis elegans |
| Q37650426 | Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer's disease |
| Q37893588 | Brief update on different roles of tau in neurodegeneration |
| Q83225179 | Cell-specific non-canonical amino acid labelling identifies changes in the de novo proteome during memory formation |
| Q36778845 | Co-immunoprecipitation with Tau Isoform-specific Antibodies Reveals Distinct Protein Interactions and Highlights a Putative Role for 2N Tau in Disease |
| Q33603862 | Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model |
| Q37407854 | Common features between diabetes mellitus and Alzheimer's disease |
| Q43660921 | Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice |
| Q26996848 | Connecting the dots between tau dysfunction and neurodegeneration |
| Q33876147 | Convergence of amyloid-beta and tau pathologies on mitochondria in vivo |
| Q33987984 | Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons |
| Q38041425 | Decoding the non-coding RNAs in Alzheimer's disease |
| Q91578534 | Decreased synthesis of ribosomal proteins in tauopathy revealed by non-canonical amino acid labelling |
| Q28506401 | Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit Calpha |
| Q28119018 | Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models |
| Q40361832 | Different tau epitopes define Abeta42-mediated tau insolubility |
| Q33307478 | Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils |
| Q90410907 | Disease-associated tau impairs mitophagy by inhibiting Parkin translocation to mitochondria |
| Q42649283 | Dissecting toxicity of tau and beta-amyloid |
| Q28507700 | Distinct role of protein phosphatase 2A subunit Calpha in the regulation of E-cadherin and beta-catenin during development |
| Q49031725 | Divergent phosphorylation pattern of tau in P301L tau transgenic mice |
| Q48429500 | Diversity, developmental regulation and distribution of murine PR55/B subunits of protein phosphatase 2A. |
| Q36513243 | Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? |
| Q35636403 | ENU mutagenesis screen to establish motor phenotypes in wild-type mice and modifiers of a pre-existing motor phenotype in tau mutant mice |
| Q42488398 | Enhanced vascular responses to adrenomedullin in mice overexpressing receptor-activity-modifying protein 2. |
| Q58027784 | Erratum: Corrigendum: Bio-orthogonal labeling as a tool to visualize and identify newly synthesized proteins in Caenorhabditis elegans |
| Q104798839 | Exosomes induce endolysosomal permeabilization as a gateway by which exosomal tau seeds escape into the cytosol |
| Q49962856 | Exosomes taken up by neurons hijack the endosomal pathway to spread to interconnected neurons |
| Q30913572 | Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease |
| Q48479400 | Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions |
| Q39777445 | Expression of truncated PrP targeted to Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia |
| Q39447040 | Extracellular Vesicles Containing P301L Mutant Tau Accelerate Pathological Tau Phosphorylation and Oligomer Formation but Do Not Seed Mature Neurofibrillary Tangles in ALZ17 Mice |
| Q37066447 | Extracellular Vesicles Isolated from the Brains of rTg4510 Mice Seed Tau Protein Aggregation in a Threshold-dependent Manner |
| Q28238356 | FGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutations |
| Q38457811 | FTD and ALS--translating mouse studies into clinical trials |
| Q43718666 | Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils |
| Q64974468 | Frontotemporal dementia mutant Tau promotes aberrant Fyn nanoclustering in hippocampal dendritic spines. |
| Q33223501 | Functional Genomics meets neurodegenerative disorders Part I: transcriptomic and proteomic technology |
| Q31005421 | Functional Genomics meets neurodegenerative disorders. Part II: application and data integration |
| Q37103035 | Functional genomics dissects pathomechanisms in tauopathies: mitosis failure and unfolded protein response |
| Q39743618 | Gateway-compatible lentiviral transfer vectors for ubiquitin promoter driven expression of fluorescent fusion proteins |
| Q40516271 | Genomic organisation, chromosomal localisation tissue distribution and developmental regulation of the PR61/B' regulatory subunits of protein phosphatase 2A in mice |
| Q34956464 | Glial cells under physiologic and pathologic conditions |
| Q42218060 | Glutamate Receptors in Alzheimer's Disease: Mechanisms and Therapies |
| Q36840001 | Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation |
| Q48630800 | Granulovacuolar degeneration and unfolded protein response in mouse models of tauopathy and Aβ amyloidosis |
| Q38129226 | How it all started: tau and protein phosphatase 2A. |
| Q34779219 | Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures |
| Q33559266 | Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment |
| Q40838026 | Immature human NT2 cells grafted into mouse brain differentiate into neuronal and glial cell types. |
| Q58028302 | Impact of β-Amyloid on the Tau Pathology in Tau Transgenic Mouse and Tissue Culture Models |
| Q58028309 | Impaired development of the Harderian gland in mutant protein phosphatase 2A transgenic mice |
| Q48436885 | Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice |
| Q47575586 | Impulsivity, decreased social exploration, and executive dysfunction in a mouse model of frontotemporal dementia |
| Q34148195 | In vivo analysis of wild-type and FTDP-17 tau transgenic mice. |
| Q28478362 | Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol |
| Q37960973 | Insights into mitochondrial dysfunction: aging, amyloid-β, and tau-A deleterious trio |
| Q37080680 | Lessons from two prevalent amyloidoses-what amylin and Aβ have in common |
| Q58027510 | Local Oxidative Damage in the Soma and Dendrites Quarantines Neuronal Mitochondria at the Site of Insult |
| Q112284038 | Low-intensity ultrasound restores long-term potentiation and memory in senescent mice through pleiotropic mechanisms including NMDAR signaling |
| Q38139701 | March separate, strike together--role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer's disease |
| Q30473576 | Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta |
| Q37961383 | MicroRNA networks surrounding APP and amyloid-β metabolism--implications for Alzheimer's disease |
| Q90179343 | Mitochondria modulatory effects of new TSPO ligands in a cellular model of tauopathies |
| Q35579318 | Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity |
| Q37064222 | Mobility and subcellular localization of endogenous, gene-edited Tau differs from that of over-expressed human wild-type and P301L mutant Tau |
| Q57131006 | Modeling ultrasound propagation through material of increasing geometrical complexity |
| Q35235869 | Modes of Aβ toxicity in Alzheimer's disease |
| Q40416715 | Molecular dissection of the paired helical filament |
| Q40656151 | Motor cortical function determines prognosis in sporadic ALS. |
| Q39088915 | Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology |
| Q37252419 | Munc18-1 is a molecular chaperone for α-synuclein, controlling its self-replicating aggregation |
| Q33605734 | Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta |
| Q43145279 | Neuronal protein with tau-like repeats (PTL-1) regulates intestinal SKN-1 nuclear accumulation in response to oxidative stress |
| Q33821316 | Neuroproteomics as a promising tool in Parkinson's disease research |
| Q43120289 | No full admission for tau to the exclusive prion club yet. |
| Q58028373 | Non-tolerance and differential susceptibility to diabetes in transgenic mice expressing major histocompatibility class II genes on pancreatic β cells |
| Q43650971 | Oligodendroglial tau filament formation in transgenic mice expressing G272V tau. |
| Q48963010 | Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice |
| Q58028320 | P2-110 Amyloid-induced neurofibrillary tangle formation addressed in vivo and in vitro |
| Q40338655 | P70 S6 kinase mediates tau phosphorylation and synthesis |
| Q90821793 | PTEN activation contributes to neuronal and synaptic engulfment by microglia in tauopathy |
| Q33798637 | PTL-1 regulates neuronal integrity and lifespan in C. elegans |
| Q37790149 | Parkinson's disease: insights from non-traditional model organisms |
| Q36948965 | Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia |
| Q58028289 | Pathogenetic mechanisms in Down Syndrome |
| Q48244476 | Pattern of tau hyperphosphorylation and neurotransmitter markers in the brainstem of senescent tau filament forming transgenic mice |
| Q37344062 | Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease |
| Q48480842 | Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains |
| Q48182654 | Possibilities for the prevention and treatment of cognitive impairment and dementia |
| Q35843373 | Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals |
| Q30578448 | Premature lethality, hyperactivity, and aberrant phosphorylation in transgenic mice expressing a constitutively active form of Fyn. |
| Q58028272 | Primary support cultures of hippocampal and substantia nigra neurons |
| Q35081058 | Profiling murine tau with 0N, 1N and 2N isoform-specific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus |
| Q34633979 | Pronuclear injection for the production of transgenic mice |
| Q47814284 | Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice |
| Q48391254 | Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines |
| Q37016360 | Quantitative Imaging of Cholinergic Interneurons Reveals a Distinctive Spatial Organization and a Functional Gradient across the Mouse Striatum. |
| Q43687951 | Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. |
| Q58028116 | Reduced secretagogin expression in the hippocampus of P301L tau transgenic mice |
| Q40497520 | Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction |
| Q33713496 | Regulation of age-related structural integrity in neurons by protein with tau-like repeats (PTL-1) is cell autonomous. |
| Q58028273 | Response to the comment ‘Iron, type 2 diabetes mellitus, and Alzheimer’s disease’ to our Visions and Reflections article ‘Common features between diabetes mellitus and Alzheimer’s disease’ |
| Q58027500 | Rodent models for Alzheimer disease |
| Q34336935 | Role for glyoxalase I in Alzheimer's disease. |
| Q43983408 | Role of hippocalcin in mediating Aβ toxicity |
| Q58028318 | Role of the protein tau in Alzheimer's disease |
| Q58028329 | S.03.01 In vivo and in vitro models of AD demonstrate a role of distinct phosphorylation sites of tau in neurofibrillary tangle formation |
| Q58028312 | S.23.02 Transgenic animal models of Alzheimer's disease |
| Q35472266 | Saitohin gene is not associated with Alzheimer's disease |
| Q36160523 | Scanning Ultrasound (SUS) Causes No Changes to Neuronal Excitability and Prevents Age-Related Reductions in Hippocampal CA1 Dendritic Structure in Wild-Type Mice |
| Q34043432 | Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model |
| Q36426980 | Sex hormone-related neurosteroids differentially rescue bioenergetic deficits induced by amyloid-β or hyperphosphorylated tau protein |
| Q47994216 | Shedding light on mitophagy in neurons: what is the evidence for PINK1/Parkin mitophagy in vivo? |
| Q45912754 | Single nucleotide variants (SNVs) define senescence-accelerated SAMP8 mice, a model of a geriatric condition. |
| Q34068459 | Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models |
| Q58028291 | Soluble Beta-Amyloid Leads to Mitochondrial Defects in Amyloid Precursor Protein and Tau Transgenic Mice |
| Q47867970 | Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn-mediated local protein translation |
| Q48461987 | Special issue on 'Cytoskeletal proteins in health and neurodegenerative disease'. |
| Q53397821 | Substrate-specific reduction of PP2A activity exaggerates tau pathology. |
| Q49104984 | Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-β. |
| Q35008256 | Tau aggregation and its interplay with amyloid-β. |
| Q58028348 | Tau and transgenic animal models |
| Q31442641 | Tau filament formation in transgenic mice expressing P301L tau. |
| Q28070250 | Tau physiology and pathomechanisms in frontotemporal lobar degeneration |
| Q28119104 | Tau promotes neurodegeneration via DRP1 mislocalization in vivo |
| Q34256620 | Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease |
| Q34102829 | Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice |
| Q27023429 | Tau-targeted treatment strategies in Alzheimer's disease |
| Q48650483 | Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice |
| Q58028359 | The Role of Protein Phosphatase 2A Catalytic Subunit Cα in Embryogenesis: Evidence from Sequence Analysis and Localization Studies |
| Q46368794 | The amyloid-β oligomer Aβ*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation. |
| Q38778723 | The frontotemporal dementia-motor neuron disease continuum |
| Q39012769 | The herbal compound geniposide rescues formaldehyde-induced apoptosis in N2a neuroblastoma cells |
| Q90091361 | The search for improved animal models of Alzheimer's disease and novel strategies for therapeutic intervention |
| Q48117016 | Transgenic and knockout models of PP2A. |
| Q35723358 | Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. |
| Q37009753 | Transgenic mice expressing the nucleoprotein of Borna disease virus in either neurons or astrocytes: decreased susceptibility to homotypic infection and disease |
| Q58028292 | Transgenic mice with ocular overexpression of an adrenomedullin receptor reflect human acute angle-closure glaucoma |
| Q38739505 | Ultrasound treatment of neurological diseases--current and emerging applications |
| Q93024737 | Ultrasound-mediated blood-brain barrier opening enhances delivery of therapeutically relevant formats of a tau-specific antibody |
| Q39014131 | Visualizing the microtubule-associated protein tau in the nucleus |
| Q36914658 | What Renders TAU Toxic |
| Q35215656 | What we can learn from animal models about cerebral multi-morbidity |
| Q38098662 | Why size matters - balancing mitochondrial dynamics in Alzheimer's disease |
| Q44534307 | beta-Amyloid induces paired helical filament-like tau filaments in tissue culture |
Search more.